CIP
ACAD icon

Cornerstone Investment Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Cornerstone Investment Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,538
Closed -$212K – 313
2026
Q1 		$212K Buy
+9,538
New +$228K 0.01% 257

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cornerstone Investment Partners's ACAD Position: Q2 2026 in Review

Cornerstone Investment Partners sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 9,538 shares — an estimated $212K sold.

Cornerstone Investment Partners first reported a position in ACAD in Q1 2026 and held it in 1 quarter. The position peaked at $212K in Q1 2026. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Cornerstone Investment Partners reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Cornerstone Investment Partners sold 9,538 Acadia Pharmaceuticals shares in Q2 2026, an estimated $212K.
  • Cornerstone Investment Partners first reported a position in Acadia Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Cornerstone Investment Partners's Acadia Pharmaceuticals position peaked at $212K in Q1 2026.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Cornerstone Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.